A Prospective Study Assessing the Efficacy and Toxicity of Stereotactic Body Radiation Therapy for Oligometastatic Bone Metastases

Joyce H Lee; Diana D Shi; Kee-Young Shin; Elizabeth Buckley; Lauren Gunasti; Emily Hall; Eileen Mann; Beverly Spicer; Yu-Hui Chen; Lubna Hammoudeh; Victoria Brennan; Mai Anh Huynh; Alexander Spektor; Monica S Krishnan; Tracy A Balboni; Lauren M Hertan

doi:10.1016/j.adro.2023.101411

A Prospective Study Assessing the Efficacy and Toxicity of Stereotactic Body Radiation Therapy for Oligometastatic Bone Metastases

Adv Radiat Oncol. 2023 Dec 6;9(4):101411. doi: 10.1016/j.adro.2023.101411. eCollection 2024 Apr.

Authors

Affiliations

¹ Department of Radiation Oncology, Dana-Farber Cancer Institute/Brigham and Women's Cancer Center, Harvard Medical School, Boston, Massachusetts.
² Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
³ Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
⁴ Knight Cancer Institute Radiation Medicine, Oregon Health and Science University, Portland, Oregon.
⁵ Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.

Abstract

Purpose: Stereotactic body radiation therapy (SBRT) is a promising treatment for oligometastatic disease in bone because of its delivery of high dose to target tissue and minimal dose to surrounding tissue. The purpose of this study is to assess the efficacy and toxicity of this treatment in patients with previously unirradiated oligometastatic bony disease.

Methods and materials: In this prospective phase II trial, patients with oligometastatic bone disease, defined as ≤3 active sites of disease, were treated with SBRT at Brigham and Women's Hospital/Dana Farber Cancer Center and Beth Israel Deaconess Medical Center between December 2016 and May 2019. SBRT dose and fractionation regimen were not protocol mandated. Local progression-free survival, progression-free survival, prostatic specific antigen progression, and overall survival were reported. Treatment-related toxicity was also reported.

Results: A total of 98 patients and 126 lesions arising from various tumor histologies were included in this study. The median age of patients enrolled was 72.8 years (80.6% male, 19.4% female). Median follow-up was 26.7 months. The most common histology was prostate cancer (68.4%, 67/98). The most common dose prescriptions were 27/30 Gy in 3 fractions (27.0%, 34/126), 30 Gy in 5 fractions (16.7%, 21/126), or 30/35 Gy in 5 fractions (16.7%, 21/126). Multiple doses per treatment regimen reflect dose painting employing the lower dose to the clinical target volume and higher dose to the gross tumor volume. Four patients (4.1%, 4/98) experienced local progression at 1 site for each patient (3.2%, 4/126). Among the entire cohort, 2-year local progression-free survival (including death without local progression) was 84.8%, 2-year progression-free survival (including deaths as well as local, distant, and prostatic specific antigen progression) was 47.5%, and 2-year overall survival was 87.3%. Twenty-six patients (26.5%, 26/98) developed treatment-related toxicities.

Conclusions: Our study supports existing literature in showing that SBRT is effective and tolerable in patients with oligometastatic bone disease. Larger phase III trials are necessary and reasonable to determine long-term efficacy and toxicities.

Abstract

Grants and funding